ArticleScientific data2023
A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer's disease.
Article in Scientific data, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Proteomics of post mortem brains in early- and late-onset Alzheimer's disease: Unraveling differential Aβ effects and potential AD biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Proteomics reveals spatial and molecular heterogeneities in advanced atherosclerotic carotid artery plaques.Nature cardiovascular research · 2026Article
- Proteomic profiling of xenobiotic and nutrient transporters in human placenta of different gestational ages.bioRxiv : the preprint server for biology · 2026Article
- Spontaneous Isomerization of Tau is Most Prevalent in Alzheimer's Disease.NeuroMarkers · 2026Article
- Proteomic profiling of human omental and subcutaneous adipose tissue in individuals with a broad range of BMI.Scientific data · 2026Article
- Is Protein Quantification and Physical Normalization Always Necessary in Proteomics?bioRxiv : the preprint server for biology · 2026Article
- Proteomic Profiling of Human Omental and Subcutaneous Adipose Tissue in Individuals with a Broad Range of BMI.bioRxiv : the preprint server for biology · 2026Article
- AUGMENTED DOUBLY ROBUST POST-IMPUTATION INFERENCE FOR PROTEOMIC DATA.The annals of applied statistics · 2025Article
- Improved quantitative accuracy in data-independent acquisition proteomics via retention time boundary imputation.bioRxiv : the preprint server for biology · 2025Article
- AUGMENTED DOUBLY ROBUST POST-IMPUTATION INFERENCE FOR PROTEOMIC DATA.bioRxiv : the preprint server for biology · 2025Article
- SMOC1 colocalizes with Alzheimer's disease neuropathology and delays Aβ aggregation.Acta neuropathologica · 2024Article
- SMOC1 colocalizes with Alzheimer's disease neuropathology and delays Aβ aggregation.Research square · 2024Article
- A Framework for Quality Control in Quantitative Proteomics.Journal of proteome research · 2024Article
- Establishing Quality Control Metrics for Large-Scale Plasma Proteomic Sample Preparation.ACS measurement science au · 2024Article
- A framework for quality control in quantitative proteomics.bioRxiv : the preprint server for biology · 2024Article
- Evaluating Proteomics Imputation Methods with Improved Criteria.Journal of proteome research · 2023Article
- Whole genome deconvolution unveils Alzheimer's resilient epigenetic signature.Nature communications · 2023Article
- Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer's disease.Nature communications · 2023Article
- A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer's disease.Scientific data · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Alzheimer's disease (AD) is a looming public health disaster with limited interventions. Alzheimer's is a complex disease that can present with or without causative mutations and can be accompanied by a range of age-related comorbidities. This diverse presentation makes it difficult to study molecular changes specific to AD. To better understand the molecular signatures of disease we constructed a unique human brain sample cohort inclusive of autosomal dominant AD dementia (ADD), sporadic ADD, and those without dementia but with high AD histopathologic burden, and cognitively normal individuals with no/minimal AD histopathologic burden. All samples are clinically well characterized, and brain tissue was preserved postmortem by rapid autopsy. Samples from four brain regions were processed and analyzed by data-independent acquisition LC-MS/MS. Here we present a high-quality quantitative dataset at the peptide and protein level for each brain region. Multiple internal and external control strategies were included in this experiment to ensure data quality. All data are deposited in the ProteomeXchange repositories and available from each step of our processing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.